Compounds of the formula (I)
1
wherein m, n, R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.
trialkylamines in liquid HF takes place readily in good yields, whereas dialkyl ethers give low yields. The latter fluorinated ethers are of interest for their low temperature properties. Our goal in this work was to prepare fluorinated aminoalkylether fluids which might combine the favorable yields of amines and properties of ethers. Several dialkylamine and alkylene units were combined in a variety of diamino
6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
申请人:Janssen Pharmaceutica NV
公开号:US11001569B2
公开(公告)日:2021-05-11
The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.